Not an era of complacency,
but of sustainability, delivery,
and control for tablets as well.

B-ReC - Bizen Release-time Control -

The release can be appropriately controlled
to ensure delivery to the targeted site.

  • High functionality
  • High absorption
  • Long-lasting

Producing the delivery according to the customer’s request

  1. B-ReCPoint 1

    Delivery function
    in the digestive tract

    図:一般錠剤とB-ReC錠の体内動態 図:一般錠剤とB-ReC錠の体内動態

    We confirmed the pharmacokinetic profile of ordinary tablets and B-ReC tablets. Ordinary tablets completely disintegrated within 90 minutes from the stomach to the duodenum, but the jejunum-disintegrating B-ReC tablets did not disintegrate in the upper small intestine (jejunum) even 180 minutes after ingestion, but in the middle small intestine after 240 minutes.

    This proves that
    the formulation can deliver the 
    functional ingredients
    to the target site in the 
    digestive tract.

  2. B-ReCPoint 2

    Release control for functional ingredients

    図:ΔAUC(血中濃度曲線下面積)とΔCmax(最高血中濃度) 図:ΔAUC(血中濃度曲線下面積)とΔCmax(最高血中濃度)

    The nature of the release control was evaluated using glucose absorbed in the upper digestive tract as a model. Eleven healthy volunteer subjects were given glucose tablets, and data on their blood glucose behavior was analyzed. The greater the sustained release, the smaller the AUC (area under the blood concentration curve) and the lower the Cmax (maximum blood concentration). This suggests that the absorption of glucose in the upper digestive tract was suppressed.

    Release control functions 
    can be produced freely.

  3. B-ReCPoint 3

    Improved bioavailability of functional ingredients


    B-ReC tablets containing vitamin C (VC) were used to verify the manner of urinary excretion of VC by sustained release in the small intestine. B-ReC tablets containing VC resulted in less urinary excretion of VC than ordinary tablets, and the total VC excretion at 24 hours after ingestion was about one-half that of ordinary tablets.
    This result suggests that the VC release of B-ReC tablets in the intestinal tract was limited, and the rapid increase of VC in the blood was suppressed, thus meaning excretion into the urine was suppressed.

    A greater amount of VC is retained in the body, suggesting increased bioavailability.